WealthPLAN Partners’s Ionis Pharmaceuticals IONS Stock Holding History

WealthPLAN Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$30	Buy	+500	New	+$27K	﹤0.01%	1699

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

WealthPLAN Partners's IONS Position: Q4 2015 in Review

WealthPLAN Partners opened a new position in Ionis Pharmaceuticals (IONS) in Q4 2015: 500 shares worth $30. The stake represents ﹤0.01% of the portfolio and ranks #1699 among its holdings.

335 funds tracked by Wall St. Rank hold IONS as of Q4 2015.

WealthPLAN Partners held 500 shares of Ionis Pharmaceuticals worth $30 as of Q4 2015.
Ionis Pharmaceuticals was a new WealthPLAN Partners position in Q4 2015.
Ionis Pharmaceuticals made up ﹤0.01% of WealthPLAN Partners's portfolio in Q4 2015, its #1699 holding.
335 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2015.

Based on WealthPLAN Partners's 13F filing for Q4 2015, filed 24 Mar 2016.